RESUMEN
Ligand-based virtual screening with a 3D pharmacophore led to the discovery of 30 novel, diverse and drug-like ligands of the human cannabinoid receptor 1 (hCB(1)). The pharmacophore was validated with a hit rate of 16%, binding selectivity versus hCB(2), and expected functional profiles. The discovered compounds provide new tools for exploring cannabinoid pharmacology.
Asunto(s)
Química Farmacéutica/métodos , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/metabolismo , Animales , Cannabinoides/química , Cannabis/metabolismo , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Ligandos , Ratones , Modelos Químicos , Estructura Molecular , Obesidad/tratamiento farmacológico , Piperidinas/farmacología , Pirazoles/farmacología , Receptor Cannabinoide CB1/química , Receptor Cannabinoide CB2/química , RimonabantRESUMEN
We describe herein the discovery and development of a series of 4-arylthieno[3,2-d]pyrimidines which are potent adenosine A(2A) receptor antagonists. These novel compounds show high degrees of selectivity against the human A(1), A(2B) and A(3) receptor sub-types. Moreover, a number of these compounds show promising activity in vivo, suggesting potential utility in the treatment of Parkinson's disease.
Asunto(s)
Antagonistas del Receptor de Adenosina A2 , Antiparkinsonianos/uso terapéutico , Diseño de Fármacos , Trastornos Parkinsonianos/tratamiento farmacológico , Pirimidinas/uso terapéutico , Antagonistas del Receptor de Adenosina A1 , Antagonistas del Receptor de Adenosina A3 , Antiparkinsonianos/síntesis química , Humanos , Modelos Químicos , Pirimidinas/síntesis química , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
A series of pyrazolo[3,4-d]pyrimidine, pyrrolo[2,3-d]pyrimidine and 6-arylpurine adenosine A(2A) antagonists is described. Many examples were highly selective against the human A(1) receptor sub-type and were active in an in vivo model of Parkinson's disease.
Asunto(s)
Antagonistas del Receptor de Adenosina A2 , Antiparkinsonianos/uso terapéutico , Diseño de Fármacos , Trastornos Parkinsonianos/tratamiento farmacológico , Purinas/uso terapéutico , Pirazoles/uso terapéutico , Pirimidinas/uso terapéutico , Antagonistas del Receptor de Adenosina A1 , Antiparkinsonianos/síntesis química , Humanos , Modelos Químicos , Purinas/síntesis química , Pirazoles/síntesis química , Pirimidinas/síntesis química , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
The (-)-(11R,2'S)-enantiomer of the antimalarial drug mefloquine has been found to be a reasonably potent and moderately selective adenosine A(2A) receptor antagonist. Further investigation of this compound has led to the discovery of a series of keto-aryl thieno[3,2-d]pyrimidine derivatives, which are potent and selective antagonists of the adenosine A(2A) receptor. These derivatives show selectivity against the A(1) receptor. Furthermore, some of these compounds have been shown to have in vivo activity in a commonly used model, suggesting the potential for the treatment of Parkinson's disease.
Asunto(s)
Antagonistas del Receptor de Adenosina A2 , Antimaláricos/uso terapéutico , Antiparkinsonianos/uso terapéutico , Trastornos Parkinsonianos/tratamiento farmacológico , Pirimidinas/uso terapéutico , Antimaláricos/síntesis química , Antiparkinsonianos/síntesis química , Humanos , Modelos Químicos , Pirimidinas/síntesis química , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
Ligand-based virtual screening led to the discovery of a new class of potent inverse agonists of the human cannabinoid receptor 1, hCB(1), which are selective versus hCB(2). These CB(1) ligands present intriguing departures from a classical CB(1) antagonist pharmacophore. Elements of SAR are discussed in this context.
Asunto(s)
Cannabinoides/síntesis química , Cannabinoides/farmacología , Receptor Cannabinoide CB1/agonistas , Cannabinoides/química , Técnicas Químicas Combinatorias , Diseño de Fármacos , Humanos , Ligandos , Estructura Molecular , Receptor Cannabinoide CB2/agonistas , Relación Estructura-ActividadRESUMEN
Database searching led to the identification of potent A(2A) antagonists which do not contain the privileged furan moiety and which show selectivity over A(1) receptors. Simple substructure searching on a proprietary database identified compounds with activities in the low nM range. A targeted approach to the identification of non-furan containing compounds resulted in the identification of two novel series, with potency, selectivity and directional SAR from screening 113 compounds.
Asunto(s)
Antagonistas del Receptor de Adenosina A2 , Furanos/química , Furanos/farmacología , Aminación , Flúor/química , Furanos/síntesis química , Furanos/metabolismo , Modelos Moleculares , Estructura Molecular , Unión Proteica , Pirimidinas/química , Pirimidinas/metabolismo , Receptor de Adenosina A2A/metabolismo , Relación Estructura-ActividadRESUMEN
A series of 1-(1-pyrrolo(iso)quinolinyl)-2-propylamines was synthesised and evaluated as 5-HT(2C) receptor agonists for the treatment of obesity. The general methods of synthesis of the precursor indoles are described. The functional efficacy and radioligand binding data for the compounds at 5-HT(2) receptor subtypes are reported. The analogue which showed the highest 5-HT(2C) binding affinity (27, 1.6nM) was found to be successful in reducing food intake in rats.
Asunto(s)
Ingestión de Alimentos/efectos de los fármacos , Isoquinolinas/farmacología , Quinolinas/farmacología , Agonistas del Receptor de Serotonina 5-HT2 , Agonistas de Receptores de Serotonina/farmacología , Animales , Fármacos Antiobesidad/farmacología , Modelos Animales de Enfermedad , Isoquinolinas/química , Pirroles/química , Quinolinas/química , Ensayo de Unión Radioligante , RatasRESUMEN
In the present study we compared the affinity of various drugs for the high affinity "agonist-preferring" binding site of human recombinant 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors stably expressed in monoclonal mammalian cell lines. To ensure that the "agonist-preferring" conformation of the receptor was preferentially labelled in competition binding experiments, saturation analysis was conducted using antagonist and agonist radiolabels at each receptor. Antagonist radiolabels ([3H]-ketanserin for 5-HT(2A) receptor and [3H]-mesulergine for 5-HT(2B) and 5-HT(2C) receptor) bound to a larger population of receptors in each preparation than the corresponding agonist radiolabel ([125I]-DOI for 5-HT(2A) receptor binding and [3H]-5-HT for 5-HT(2B) and 5-HT(2C) receptor binding). Competition experiments were subsequently conducted against appropriate concentrations of the agonist radiolabels bound to the "agonist-preferring" subset of receptors in each preparation. These studies confirmed that there are a number of highly selective antagonists available to investigate 5-HT2 receptor subtype function (for example, MDL 100907, RS-127445 and RS-102221 for 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors respectively). There remains, however, a lack of highly selective agonists. (-)DOI is potent and moderately selective for 5-HT(2A) receptors, BW723C86 has poor selectivity for human 5-HT(2B) receptors, while Org 37684 and VER-3323 display some selectivity for the 5-HT(2C) receptor. We report for the first time in a single study, the selectivity of numerous serotonergic drugs for 5-HT2 receptors from the same species, in mammalian cell lines and using, exclusively, agonist radiolabels. The results indicate the importance of defining the selectivity of pharmacological tools, which may have been over-estimated in the past, and highlights the need to find more selective agonists to investigate 5-HT2 receptor pharmacology.